Loxo Oncology, Inc. (NASDAQ:LOXO) insider Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $81.19, for a total transaction of $250,227.58. Following the transaction, the insider now directly owns 1,541 shares of the company’s stock, valued at $125,113.79. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Naarden Jacob Van also recently made the following trade(s):

  • On Tuesday, November 28th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $74.50, for a total transaction of $229,609.00.
  • On Tuesday, October 31st, Naarden Jacob Van sold 1,541 shares of Loxo Oncology stock. The shares were sold at an average price of $86.52, for a total transaction of $133,327.32.
  • On Tuesday, September 19th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $89.00, for a total transaction of $274,298.00.

Loxo Oncology, Inc. (NASDAQ LOXO) opened at $79.25 on Tuesday. Loxo Oncology, Inc. has a 1-year low of $30.01 and a 1-year high of $95.92.

A number of institutional investors have recently added to or reduced their stakes in the stock. FMR LLC grew its stake in Loxo Oncology by 12.1% in the 2nd quarter. FMR LLC now owns 4,394,827 shares of the biopharmaceutical company’s stock valued at $352,420,000 after acquiring an additional 472,814 shares during the period. BlackRock Inc. grew its stake in Loxo Oncology by 20.6% in the 2nd quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock valued at $128,534,000 after acquiring an additional 273,291 shares during the period. Alliancebernstein L.P. grew its stake in Loxo Oncology by 50.2% in the 2nd quarter. Alliancebernstein L.P. now owns 936,790 shares of the biopharmaceutical company’s stock valued at $75,121,000 after acquiring an additional 312,988 shares during the period. Vanguard Group Inc. grew its stake in Loxo Oncology by 24.7% in the 2nd quarter. Vanguard Group Inc. now owns 914,719 shares of the biopharmaceutical company’s stock valued at $73,351,000 after acquiring an additional 181,471 shares during the period. Finally, Lord Abbett & CO. LLC grew its stake in Loxo Oncology by 372.0% in the 2nd quarter. Lord Abbett & CO. LLC now owns 739,540 shares of the biopharmaceutical company’s stock valued at $59,304,000 after acquiring an additional 582,862 shares during the period. 99.98% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently weighed in on LOXO shares. Citigroup cut their target price on shares of Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a report on Thursday, November 16th. BTIG Research reaffirmed a “buy” rating and set a $102.00 target price (up from $75.00) on shares of Loxo Oncology in a report on Friday, September 29th. Cowen reaffirmed a “buy” rating on shares of Loxo Oncology in a report on Thursday, September 28th. JMP Securities lowered shares of Loxo Oncology from an “outperform” rating to a “market perform” rating and cut their target price for the company from $83.12 to $17.14 in a report on Tuesday, August 29th. They noted that the move was a valuation call. Finally, William Blair started coverage on shares of Loxo Oncology in a report on Tuesday, November 28th. They set an “outperform” rating for the company. Two analysts have rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $90.57.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/loxo-oncology-inc-loxo-insider-naarden-jacob-van-sells-3082-shares-of-stock/1772458.html.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.